LCA, in concentrations corresponding to its serum or breast tissue concentrations (30–50 nM or < 1 μM, respectively [120,188]), exerts antineoplastic effects on breast cancer cells by inhibiting epithelial-to-mesenchymal transition, vascular endothelial growth factor (VEGF) production, metastasis formation, induced antitumor immunity, and elicited changes in metabolism [120]. Here, VEGFA is linked to breast carcinoma.